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Abstract
Background: Lynch syndrome (LS) is a hereditary condition characterized by
a high risk of colorectal cancer, endometrial cancer, and other neoplasia asso-
ciated with germline alterations in DNA mismatch repair genes. The classical
genetic diagnostic strategy for LS consists of the Sanger sequencing of genes asso-
ciated with the suspected syndrome. Next-generation sequencing (NGS) enables
the simultaneous sequencing of a large number of hereditary cancer genes. Here,
we aimed to studywhether other germline pathogenic variants of hereditary can-
cer genes are present in patients with LS.
Methods: A cohort of 84 probands with a previous genetic diagnosis of LS by
Sanger sequencing was reanalyzed using NGS via a commercial panel of 94
hereditary cancer genes by hybrid capture. The American College of Medical
Genetics and Genomics criteria were used to classify the clinical significance of
the variants. The findings of NGS were confirmed by Sanger sequencing. When
possible, genetic analyses of the new findings in the proband’s relatives were also
performed by Sanger sequencing.
Results: We identified five families (6%), out of 84, with at least two
germline pathogenic variants conferring to high or moderate risk in differ-
ent dominant cancer-predisposing genes: [MLH1-BRCA2-NBN], [MLH1-BRCA1],
Abbreviations: ACMG, American College of Medical Genetics and Genomics; CI, Confidence interval; CRC, Colorectal cancer; EC, Endometrial
cancer; EUS, Endoscopic ultrasound; LS, Lynch syndrome; MINAS, Multilocus-Inherited-Neoplasia-Allele Syndrome; MMR, Mismatch repair; MRI,
Magnetic resonance imaging; NCBI, National Center for Biotechnology Information; NGS, Next-generation sequencing; OR, Odds ratio; PSA,
Prostate-specific antigen
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[MSH2-ATM], [MSH6-NF1], and [MLH1-FANCA]. Interestingly, only one out
of these five families exhibited a clinical phenotype associated with the new
pathogenic variants. The family with three pathogenic variants of the [MLH1-
BRCA2-NBN] genes showed a high aggregation of tumors associated with LS and
breast and ovarian cancer syndrome.
Conclusions: Our results showed that the co-occurrence of more than one
pathogenic variant in cancer-predisposing genes was remarkable among cases of
LS. Inmost cases, no clinicial manifestations were associated with the secondary
pathogenic variants. Further studies are needed to confirm these findings and
elucidate their clinical impact. Reanalysis of LS families should be considered
only in families with mixed clinical phenotypes.
KEYWORDS
cancer panel, hereditary cancer, lynch syndrome, moderate penetrance genes, multilocus
inherited neoplasia alleles syndrome, next-generation sequencing, secondary findings
1 BACKGROUND
Lynch syndrome (LS [MIM:120435]) is a hereditary con-
dition characterized by a high risk of colorectal cancer
(CRC), endometrial cancer (EC), and other neoplasia
that are frequently diagnosed at an early age. LS is the
most common hereditary CRC syndrome, accounting for
approximately 1%–3% of all cases of CRC. In the major-
ity of cases, germline variants in one of the DNA mis-
match repair (MMR) genes [MLH1 (MutL homolog 1),
MSH2 (MutS Homolog 2), MSH6 (MutS homolog 6), and
PMS2 (PMS1 Homolog 2)] are responsible for this syn-
dromewhich exhibits autosomal dominant inheritance [1].
LS is characterized by incomplete penetrance and vari-
able expressivity. There is high variability in cancer risk
among the carriers of MMR gene pathogenic variants [2].
The causes of this variability are unknown, although they
might be explained by age, sex, modifier genes, epigenetic
changes, or environmental factors. The co-occurrence of
other pathogenic variants may explain, in some cases,
the absence of genotype–phenotype correlations [3].
Moreover, there is increasing evidence of the polygenic
heritability of CRC risk, which might function as a
penetrance-modifying factor in cases of LS [4].
The conventional model used for hereditary cancer
risk assessment involves the identification of individuals
whose histories fulfill the clinical criteria for a specific syn-
drome, followed by targeted germline testing of the gene(s)
associated with that syndrome exclusively. The identifica-
tion of a germline pathogenic variant in the probands and
their relatives enables their inclusion in cancer surveil-
lance programs. Such programs are effective in reducing
cancer mortality in these families. Furthermore, family
members who do not carry the pathogenic variant can be
treated safely as low-risk individuals, avoiding unneces-
sary screening and preventing anxiety in these individuals.
Currently, multigene panel testing using next-generation
sequencing (NGS) technologies tests multiple hereditary
cancer genes in parallel, with lower economic burden and
less time-consuming approaches [5].
At present, an increasing number of cases that carry
two or more inherited cancer-predisposing alleles in the
same individual are being described and are termed mul-
tilocus inherited neoplasia alleles syndrome (MINAS) [6].
This scenario has been reported in various disorders with
both distinct and overlapping phenotypes. Although the
frequency of MINAS is predicted to be low, such cases are
probably underdiagnosed because of the standard diagnos-
tic procedure used in clinical practice [6, 7].
This present study aimed to estimate the prevalence
of the co-occurrence of pathogenic variants in cancer-
predisposing genes in a cohort of LS probands with
pathogenic variants in MMR genes. The underlying objec-
tive was to deepen the understanding and achieve a more
precise assessment of the cancer risk in these families.
Herein, we report five cases with multiple heterozygous




A descriptive retrospective and analytical study was
performed using a comprehensive genetic analysis of
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hereditary cancer genes to identify additional pathogenic
variants in patients with LS.
2.2 Patients
The cohort of patients included in this study corresponded
to probands with a suspicion of LS based on their per-
sonal or family history of cancer. All families included here
fulfilled the revised Bethesda criteria and were referred
to and attended a Genetic Counseling in Cancer consul-
tancy from the Hereditary Cancer Program of the Valen-
cian Region (Spain) between May 2005 and December
2016. The total number of patients with suspected LS
with pathogenic/likely pathogenic variant in MMR genes
was 189. All participants signed proper informed consent
for genetic diagnosis. About 85% of them also signed the
informed consent for the Valencian Biobanks Network
(n = 161). Patients included in this group were consid-
ered for the current study. These individuals also con-
sented to participate in any future research project related
to hereditary cancer. Participation implies the use of bio-
logical samples and associated clinicopathological infor-
mation. The patientťs autonomy and desire to know or to
ignore secondary findings were respected according to the
Spanish laws. This study was approved by the correspond-
ing Ethical and Scientific Committees. Eleven DNA sam-
ples were excluded because of insufficient DNA quantity
(n = 150). Random selection of the 84 patients was car-
ried out among the 150 individualswith enoughDNAqual-
ity who signed the Valencian Biobank Network informed
consent, due to funding limitations (Supplementary
Table S1).
2.3 Genetic diagnosis procedures
For all participants, a genetic diagnosis of LS was estab-
lished previously by Sanger sequencing after the applica-
tion of standard procedures of clinical selection criteria,
MMR immunohistochemical screening, and other com-
plementary analyses (i.e., assessment of MLH1 methyla-
tion and BRAF-V600E mutation in tumors) [1].
2.3.1 NGS library preparation and
bioinformatics analysis
Ninety-four genes associated with hereditary cancer syn-
dromes were sequenced via NGS in DNA extracted from
blood cells (TruSight Cancer Illumina kit; Illumina, San
Diego, CA, USA) (Supplementary Table S2). Libraries
were generated using TruSight-RapidCapture (Illumina),
according to the manufacturer’s protocol. Sequencing
was performed on an Illumina-MiSeq apparatus and
sequence data were analyzed using the on-instrument
MiSeq-Reporter (Illumina) software. BAM files were cre-
ated after the alignment of FASTQ files to the human
reference genome (hg19, NCBI_build GRCh37) using the
Burrows–Wheeler aligner. The Genome Analysis Toolkit
was used to perform variant calling (VCF_files), and the
VariantStudio software (Illumina) was used to manage the
data after the application of a custom pipeline for vari-
ant filtering. Briefly, we considered a minimal coverage
of 20×; a Q score of 30; a region of interest correspond-
ing to the coding sequence ± 10 nt, and; variants with an
allelic population frequency ≤5%, according to the 1000
Genomes Project and gnomAD. The threshold for the vari-
ant allele frequency was >0.30. The Integrative Genomics
Viewer was used for the manual review of the variants of
interest.
2.3.2 Pathogenic assessment of genetic
variants
The American College of Medical Genetics and Genomics
(ACMG) criteria were used to classify the clinical signif-
icance of the variants [8]. The genomic variant search
engine VarSome [9] and the public archive of the rela-
tionships among human sequence variations and pheno-
types with supporting evidence, ClinVar [10], were used
to facilitate the variant classification process. Briefly, after
the application of population-frequency filters, we fil-
tered variants with the followingmolecular consequences:
frameshift, nonsense, consensus splice sites, start loss and
stop gain, in-frame in/del, and missense variations. We
screened for these variants in the VarSome and ClinVar
databases and reviewed the classifications offered consid-
ering the criteria provided. The variants that were classi-
fied in ClinVar as being pathogenic or likely pathogenic
by an expert panel or with multisource consistency were
considered as pathogenic or likely pathogenic in the cur-
rent study. Variantswith conflicting interpretations among
submitters were investigated in-depth, considering the
VarSome classification and the evidence of pathogenicity
found in all the integrated resources.
All pathogenic variants detected here were confirmed
by Sanger sequencing. When possible, genetic analyses of
the new findings in the proband’s relatives were also per-
formed by Sanger sequencing.
In this present study, we did not analyze variants in
genes with high homology to pseudogenes, such as PMS2.
We also excluded the analysis of copy number variations.
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2.4 Patient follow-up
Within the operation of the Hereditary Cancer Program of
the Valencian region, the annual update of the pedigrees
and the monitoring of adherence to the follow-up recom-
mendations were contemplated by phone and reviewing
medical records.
2.5 Statistical analysis
Descriptive statistics of categorical variables are presented
as frequencies and proportions. The association between
qualitative variables was analyzed using the chi-squared
test, followed by Fisher’s exact test. Statistical analysis was
performed using R (The R Project for Statistical Comput-
ing: https://www.r-project.org/), and a confidence level
P < 0.05 was used.
3 RESULTS
A cohort of 84 LS probands with previously characterized
pathogenic germline variants in theMLH1 (n= 36),MSH2
(n = 31), andMSH6 (n = 17) genes was studied.
3.1 General results in the NGS analysis
The average coverage at 20× of the 255 Kb target sequence
was 96.2%. A total of 23,664 variants passed the initial
qualifying criteria. After the application of our custom
pipeline, we compiled 1020 variants for classification based
on their clinical significance, which revealed that 84%
(n = 852) of them were benign or likely benign variants,
8% (n = 79) had uncertain significance, and 9% (n = 87)
were pathogenic or likely pathogenic variants (including
MMR pathogenic variants) (Supplementary Table S3). The
raw data have been uploaded to the NCBI Sequence Read
Archive, which is a public repository of NGS data, coded as
PRJNA594841.
Genes containing homology with pseudogenes, such as
NF1 (Neurofibromin 1) or SDHA (Succinate Dehydroge-
nase Complex Flavoprotein Subunit A), were not excluded
from further analysis because of the good quality of the
results. We obtained good coverage of specific reads that
were mapped to these genes. Only PMS2 was disregarded
because the majority of its coding sequence had low map-
ping quality, except for exons 6–8, where no pathogenic or
likely pathogenic variants were detected.
All pathogenic variants in the MMR genes previ-
ously detected by Sanger sequencing were confirmed
by NGS, except for two MSH2 splicing variants. These
variants (c.942+2T>A and c.942+3A>T) were missed
in the four probands who were heterozygous for any
of them (LS18, LS56, LS60, and LS70; Supplementary
Table S1). Both variants were located in the intron
5 of MSH2, near a difficult-to-analyze homopolymer
stretch of 26 adenine residues, and are frequently
missed [11].
3.2 Identification of additional variants
in other cancer predisposition genes
In addition to the known pathogenic variants in MMR
genes, we found additional five heterozygous pathogenic
variants in five patients. These variants were associ-
ated with different hereditary cancer syndromes. The
new pathogenic variants detected in these patients with
LS were classified according to their nature, frequency,
and reported clinical significance. The evidence used
for the classification of the new pathogenic and likely
pathogenic variants is presented in Table 1. Briefly,
four of them generated premature stop codons: three
frameshift variants in ATM (ATM Serine/Threonine
Kinase) [c.6711_6715delGGAAA], FANCA (FA Comple-
mentation Group A) [c.1115_1118delTTGG], and NF1 (Neu-
rofibromin 1) [c.5129_5141del], and one nonsense vari-
ant in NBN (Nibrin) [c.2140C>T]. Moreover, one splice
variant in the BRCA1 (BRCA1 DNA Repair Associated)
gene [c.5152+5G>A] was detected. Three of these vari-
ants (NBN, BRCA1, and FANCA) were classified as
pathogenic/likely pathogenic by VarSome and ClinVar,
two (NF1 and ATM) were not reported by ClinVar
but were classified as pathogenic/likely pathogenic by
VarSome.
All of the pathogenic and likely pathogenic variants
found are rare or extremely rare in the normal popula-
tion. None of these variants have been reported in our
control population database, which includes 1041 healthy
individuals from the Collaborative Spanish Variant Server
database. The only variant described in the gnomAD
database (filters used: gnomAD v2.1.1-non-cancer and
European non-Finnish population) wasNBN [c.2140C>T],
with very low frequency: five alleles were detected among
the 102,568 alleles sequenced. Significant frequency differ-
ences were observed between our LS cohort and gnomAD
(Table 1).
We were able to test 26 relatives of these probands
(range, 1-11 relatives per family) for pathogenic variants
in MMR and secondary genes. We found 10 (38%) posi-
tive individuals for the newly detected pathogenic variants
(Figures 1 and 2).
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(1/6)
Symbols: (†) indicates that LS9 is not a carrier of this BRCA2 pathogenic variant. The ClinVar stars represent the aggregate review status onweb pages: (3) reviewed
by an expert panel; (2) two or more submitters with assertion criteria and evidence (or a public contact) provided the same interpretation; (1) multiple submitters
provided assertion criteria and evidence (or a public contact), but there are conflicting interpretations, or one submitter provided an interpretation with assertion
criteria and evidence (or a public contact).
Databases used: ClinVar: Clinical Variation (https://www.ncbi.nlm.nih.gov/clinvar/); CSVS: Collaborative Spanish Variant Server (http://csvs.babelomics.org/);
gnomAD: The Genome Aggregation Database: (http://gnomAD.broadinstitute.org/); VarSome: the Human Genomics Community (https://varsome.com/)
Abbreviations: BC, breast cancer; BrC, brain cancer; CRC, colorectal cancer; EC, endometrial cancer; HBOC, hereditary breast, and ovarian cancer syndrome; LC,
lung cancer; LP, likely pathogenic; NF1, neurofibromatosis type 1; NR, not reported; OC, ovarian cancer; P, pathogenic; PC, pancreatic cancer; PM1, PM2, PM4,
moderate evidence of pathogenicity; PP2, PP3, PP5, supporting evidence of pathogenicity; PS3, strong evidence of pathogenicity; PVS1, very strong evidence of
pathogenicity; ThC, throat cancer; VUS, variant of uncertain significance.
3.3 Clinical phenotype in families with
co-occurrent pathogenic variants
Family (F-LS9) fulfilled the criteria for LS (Amsterdam-II)
and hereditary breast and ovarian cancer. Pathogenic
variants that are responsible for these syndromes were
previously detected in this family.MLH1: c.1717_1718delGT;
p.(Val573SerfsTer19) was initially identified in the LS9
proband, who had diagnoses of endometrial and breast
cancers at the ages of 46 and 49 years, respectively.
FERRER-AVARGUES et al. 223
F IGURE 1 Pedigree of family LS9. The pathogenic variants found in the family are shown at the top. Filled symbols indicate patients
affected by cancer (each color refers to a specific type). Age when the pedigree was drawn, age of death (symbol “ɨ”), and age at diagnosis, when
available, are also detailed. The proband is marked by an arrow. Carrier status was studied in the available relatives, and those carrying or not
carrying the pathogenic variants are marked with + and –, respectively: in black for MMR gene variant, blue for the second, and red for the
third pathogenic/likely pathogenic variant, if any. BC, breast cancer; BrC, brain cancer; CRC, colorectal cancer; EC, endometrial cancer; MMR,
mismatch repair; OC, ovarian cancer; ThC, throat cancer
BRCA2: c.3942dupT; p.(His1165SerfsTer19) was originally
detected in her elder sister, who was diagnosed with
breast and ovarian cancers at the ages of 60 and 64 years,
respectively. The LS9 individual did not carry the BRCA2
variant detected in the family, despite a diagnosis of breast
cancer at the age of 49 years. In this study, we identified
a pathogenic variant with moderate penetrance in NBN
[c.2140C>T; p.(Arg714Ter)] that may be the underlying
cause of the breast tumor. Another six relatives (including
four females) carried this NBN pathogenic variant and,
consequently, have an increased genetic risk for breast
cancer (Table 1). Details on the genotypes and clinical
phenotypes of the remaining relatives are shown in
Figure 1.
In contrast, patient LS44 who was diagnosed with CRC
at the age of 47 is the only NF1-variant carrier in her family.
A recent physical examination looking for clinical charac-
teristics of neurofibromatosis type 1 had been performed
in patient LS44, and no signs of the disease were detected.
We reviewed again the medical history, and no clinical
manifestation of neurofibromatosis was observed. Besides,
no clinical records related to associated phenotypes were
found in the other three families.
In summary, only one out of the five families in whom a
second pathogenic variant was detected showed a clinical
phenotype that was associated with the second pathogenic
variant (Table 1, Figure 1, and Figure 2).
4 DISCUSSION
To the best of our knowledge, this was the first study
to analyze a comprehensive panel of cancer-predisposing
genes by NGS among LS probands who had already been
diagnosed by Sanger sequencing. In this present study,
we found that ∼6% of LS families with co-occurrent
pathogenic variants in non-MMR hereditary cancer genes.
A better knowledge of the architecture of pathogenic
genetic variants for cancer predisposition is essential for
more precise risk estimation and personalized counseling
for the patients and their families, including adequate can-
cer prevention and surveillance strategies.
Here, the number of LS probands with a second
pathogenic variant for cancer predispositionwas unexpect-
edly high. Five families out of 84 (6%) had at least two
germline pathogenic/likely pathogenic variants: [MLH1-
BRCA2-NBN], [MLH1-BRCA1], [MLH1-FANCA], [MSH2-
ATM], and [MSH6/NF1].
Two of the non-MMR pathogenic variants identified
in this study (2/84; 2.46%) were located in genes that are
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F IGURE 2 Pedigrees of the Lynch syndrome families with a second pathogenic variant in other hereditary cancer genes: A) Pedigree of
family F-LS15; B) Pedigree of family F-LS30; C) Pedigree of family F-LS44; D) Pedigree of family F-LS49 The pathogenic variants found in the
family are shown at the top. Filled symbols indicate patients affected by cancer (each color refers to a specific type). Age when the pedigree
was drawn, age of death, and age at diagnosis, when available, are also detailed. The proband is marked by an arrow. Carrier status was studied
in the available relatives, and those carrying or not carrying the pathogenic variants are marked with + and –, respectively: in black for the
MMR gene pathogenic variant, and in red for the second pathogenic variant. BoC, bone cancer; BrC, brain cancer; CRC, colorectal cancer; EC,
endometrial cancer; GC, gastric cancer; LC, lung cancer; MMR, mismatch repair; PC, pancreatic cancer; TyC, thyroid cancer
considered as having high penetrance for hereditary breast
and ovarian cancer (two variants in BRCA1) and neurofi-
bromatosis type 1 (one variant inNF1). Pathogenic variants
in NF1 are also considered a moderate risk for breast can-
cer [12, 13]. Moreover, an additional three pathogenic
variants were found in genes of moderate penetrance for
breast cancer (ATM, NBN, FANCA) [12–15] (Table 1).
Furthermore, the heterozygous recurrent pathogenic
variant c.1187G>A; p.Gly396Asp in the MUTYH gene was
detected in case LS41, a female patient who was diagnosed
with endometrial cancer at age of 51 years and belongs
to a family fulfilling the Bethesda criteria (Supplemen-
tary Table S3). This gene is responsible for attenuated
polyposis and CRC with a recessive mode of inheritance
(MUTYH-associated polyposis syndrome). A low cancer
risk effect ofMUTYHmonoallelic pathogenic variants has
been described [16]. Moreover, it has been suggested that a
monoallelic pathogenic variant at theMUTYH gene could
confer additional risk of CRC for carriers of an MMR gene
pathogenic variant alone. The evidence supporting this
is still insufficient [17]. In any case, the few studies in
this regard suggest a digenic inheritance of concomitant
heterozygous pathogenic variants in MSH6 and MUTYH
that confer an increased risk of colorectal cancer. In this
regard, there is no data available on endometrial cancer.
Consequently, this heterozygous case was not considered
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important in our study. Thus, our results showed that
6% (5/84) of the LS probands with pathogenic variants
in MMR genes carried pathogenic variants in other
genes associated with a moderate/high risk of different
hereditary cancers.
Five of the second pathogenic variants are considered
to have moderate penetrance for breast cancer (ATM,
FANCA,NBN, andNF1 variants) [12–15]. This could confer
an increase in breast cancer risk in carriers. Cumulative
evidence suggests that monoallelic mutations in FANCA
may predispose to breast cancer. A recent study performed
by del Valle et al. [15] reports an odds ratio of 3.14 with a
95% confidence interval of 1.40-6.17 (P = 0.003) for breast
cancer risk. The associated cancer risk for these variants
should also be considered in the surveillance protocols [13].
None of the 84 probands carried a second pathogenic
variant in MMR genes, confirming the low prevalence of
carriers with pathogenic variants in two different MMR
genes among classical LS probands, especially when the
sequencing was performed by Sanger and guided by the
immunohistochemistry results ofMMRprotein expression
in tumor tissues [18].
The known prevalence of MINAS is low, although it has
probably been underdiagnosed because the standard clin-
ical practice consists of testing candidate inherited cancer
genes sequentially until a pathogenic variant is detected.
In a recent review, the authors reviewed 82 cases with
co-occurrence of pathogenic variants in different cancer-
predisposing genes in the literature and reported another
five new cases with mixed clinical phenotypes [6]. More-
over, they created a specific public database to compile this
kind of case. To date, the database contains 103 entries [19].
More recently, Whitworth et al. [20] reported that up to 3%
(2/67) of patients with multiple primary tumors had evi-
dence of MINAS.
Conversely, Stradella et al. [21] performed an important
prospective study inwhich they found 13 newMINAS cases
out of 1023 unrelated cases with suspicion of hereditary
cancer using an extended NGS gene panel. Interestingly,
10 of these MINAS cases presented with clinical manifes-
tations associated with only one of the pathogenic variants
identified at the time of diagnosis. The authors concluded
that patients with two pathogenic variants usually do not
exhibit more severe clinical manifestations, and recom-
mended further analysis and follow-up of those patients
to obtain an improved knowledge of the clinical impact
of MINAS [21]. In the study reported by Stradella et al.
[21], 63 probands carried a pathogenic/likely pathogenic
variant in MMR genes. In two of them (3.2%), a sec-
ond pathogenic/likely pathogenic variant was detected
in another hereditary cancer gene. That study [21] and
ours have some methodological dissimilarities that could
explain the differences in the results obtained: in the study
of Stradella et al. [21], the cohort was prospective, whereas
in ours it was retrospective. Moreover, the sample size
of our study was slightly larger (63 vs. 84 LS probands),
the NGS gene panels were different (135 vs. 94 genes),
and the pipelines used for result interpretation were
distinct.
In our work, the finding of a second pathogenic vari-
ant in cancer-predisposing genes was also unexpected,
considering the patients’ medical histories. There was no
clinical suspicion of a second cancer syndrome in any of
the families included here, except for F-LS9. This family
is a paradigm of the complexity of genetic risk manage-
ment in cancer. Two hereditary cancer syndromes coex-
ist in the same family with previously described causal
genetic alterations, i.e., LS (MLH1) and hereditary breast
and ovarian cancer (BRCA2). Individual LS9 was diag-
nosed with endometrial and breast cancers (at the ages
of 46 and 49 years, respectively), and she did not carry
the BRCA2 pathogenic variant of the family. Interest-
ingly, in this present study, we were able to identify a
new pathogenic variant in the NBN gene associated with
breast cancer in this patient, which could help explain this
event.
The genotypic scenario presented by family LS9, with
the combination of three pathogenic alterations in three
different hereditary cancer genes, is extremely complex.
None of the 10 analyzed relatives were carriers for any
of the three pathogenic variants identified in this family,
which implies that all of themhave amoderate-to-high risk
of developing different types of tumors. In such cases, per-
sonalized cancer surveillance programs are mandatory to
reduce the impact of the disease.
Genotype-phenotype correlation is essential for diag-
nosing genetic disease in a patient known to carry a
disease-associated genetic variant [22]. We expected to
find a stronger genotype–phenotype correlation for the
secondary pathogenic alleles found using an agnostic
approach. In some cases, the lack of a clinical pheno-
type associated with the risk conferred by the secondary
genetic alterations might be caused by the young age of
the proband, incomplete penetrance, the small family size,
insufficient available information about carrier status in
the relatives, or the absence of a comprehensive clinical
examination of probands and relatives, to detect expected
clinical manifestations. In unusual clinical circumstances,
such as MINAS, the possibility of de novo or mosaicism
mutations cannot be ruled out. In this regard, our data,
which were obtained from the relatives tested in the five
families with more than one pathogenic variant in differ-
ent hereditary cancer genes, showed that, at least in two
of these families, the new pathogenic variants were not de
novo mutations (LS9 and LS30). At this time, we do not
possess information to determine the de novo or inherited
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status of the new pathogenic variants in the remainder of
the families (Figure 2).
Pathogenic germline alterations in actionable genes
should motivate specific clinical surveillance for carriers.
According to the Spanish laws, the patient’s autonomy
and desire to know or to ignore the genetic results from
research projects were respected. Those who manifested
their right to know about the actionable results from a
research project were contacted and received adequate
genetic counseling. According to the Spanish Society of
Medical Oncology, for BRCA1 and BRCA2women carriers,
annual breast contrast magnetic resonance imaging (MRI)
at the age of 30-70 years is recommended. Semi-annual
transvaginal ultrasound and CA125 tumor marker assess-
ment surveillance may be considered from the age of 30 as
ovarian cancer screening. For men, consider mammogra-
phy in the case of gynecomastia. Other cancer screenings
include annual screening with prostate-specific antigen
(PSA) for prostate cancer from the age of 40 years is rec-
ommended in BRCA2, and also offered to male BRCA1 car-
riers. For pancreatic cancer, cancer surveillancewith endo-
scopic ultrasounds and MRI in carriers with a first-degree
relative with pancreatic cancer from the age of 50 or 10
years before the youngest diagnosis in the family is recom-
mended. Skin and eye examination for melanoma screen-
ing are also recommended according to personal/familiar
risk factors [23].
In general, breast screening MRI is recommended for
women with a >20% lifetime breast cancer risk, includ-
ing those with mutations in highly penetrant genes and
the majority of moderately penetrant genes, like ATM,
NBN, and NF1. No data are available on the benefit of risk-
reducing mastectomy. This procedure may be considered
based on family history. Screening for other cancers (ovar-
ian, pancreatic, or prostate cancers) is not recommended
in the absence of familial antecedents [13]. For NF1 unaf-
fected mutation carriers, annual physical and eye exami-
nations for every age is recommended [12]. A significant
association with the risk of breast and ovarian cancer have
been found inFANCAmutation carriers [15]. Nevertheless,
FANCA is not widely considered as a moderate risk gene,
and no surveillance recommendations have been estab-
lished. In any case, women should be encouraged to par-
ticipate in breast cancer screening.
Most hereditary cancer-predisposing syndromes are
Mendelian disorders in which the phenotypes are complex
traits because of the effects of additional independently
inherited genetic variations and/or environmental effects.
These factors might be responsible for the absence of cor-
relations between the genotypes and clinical phenotypes
[24]. The concept of polygenic risk score is being intro-
duced in the field of hereditary cancer. This concept tries
to integrate the cumulative effects of moderate- and high-
penetrance germline variants for a better understanding of
the architecture of the genetic risk in patients [25].
Our knowledge regarding hereditary cancer syndromes
is mainly based on high-risk populations and shows that
most of these syndromes have incomplete penetrance
and variable expressivity [1]. General population data
about the prevalence of high-penetrance pathogenic alle-
les for hereditary diseases suggest an underestimation of
pathogenic allele prevalence and consequently, an over-
estimation of their real penetrance [26]. Moreover, an
increasing overlap in the clinical phenotype among differ-
ent hereditary cancer syndromes is being reported [7, 27,
28]. The information generated by massive genetic anal-
yses is revealing a new dimension and a more complex
view of the genetics reality, thus changing the classical
paradigms in this field of study [26–28].
An important limitation of this study was that CNV
alterations and a gene containing pseudogenes (PMS2)
were not analyzed. Amore comprehensive studywill likely
offer a higher diagnostic yield regarding the detection of
various pathogenic variants in hereditary cancer genes
within a family.
5 CONCLUSIONS
In summary, our results showed that the prevalence of sec-
ondary pathogenic variants in other non-MMR hereditary
cancer genes among LS cases is remarkable (about 6%).
Further studies are needed to confirm this finding and elu-
cidate its clinical impact. According to our results, we sug-
gest the reanalysis of LS families only if the pedigree sug-
gests a cancer predisposition beyond that explained by LS.
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